MarketCap
Facebook
X
Telegram
Sage Therapeutics Income Statement 2024-2011 | SAGE
Brief overview of profit and loss at Sage Therapeutics
This overview is based on financial performance over the past five years. According to figures from Sage Therapeutics, revenue changed from $6.9 million to $41.2 million over five years. The five-year change reached +500.5%, while CAGR stood at 43.1%. This pace points to rapid expansion of the business.
Over the period, EBITDA shifted from −$706 million to −$431 million, a change of +38.9%. Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin moved from −10277.2% to −1045.8%. A wider margin confirms stronger operating efficiency.
The net financial result changed from −$680 million to −$401 million. The loss narrowed, although sustainable profitability has not yet returned.
Market capitalization changed from 3.4 billion dollars to 434 million dollars (−87.2%). Financial performance is stronger than the share-price trend.
Summary assessment
The results present an uneven picture without one dominant signal. Key strengths include a larger revenue base, improving net profitability and an improving EBITDA margin. The most visible risks are a weaker market valuation and a low EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Sage Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
434 M | 1.54 B | 2.65 B | 2.5 B | 4.5 B | 3.4 B | 6.12 B | 7.04 B | 1.54 B | 933 M | 871 M | - | - | - |
Shares |
60.8 M | 59.8 M | 59.3 M | 58.7 M | 52 M | 50.8 M | 46.1 M | 38.1 M | 33.5 M | 27.8 M | 21.6 M | - | - | - |
Historical Prices |
7.15 | 25.7 | 44.7 | 42.5 | 86.5 | 72.2 | 95.8 | 165 | 51.1 | 58.3 | 36.6 | - | - | - |
Net Income |
-401 M | -541 M | -533 M | -458 M | 606 M | -680 M | -373 M | -270 M | -159 M | -94.5 M | -33.8 M | -18.3 M | -9.63 M | - |
Revenue |
41.2 M | 86.5 M | 7.69 M | 6.31 M | 1.11 B | 6.87 M | 90.3 M | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | 6.47 M | - | - | - | - | - | - | - | - |
Operating Income |
-432 M | -580 M | -547 M | -461 M | 596 M | -708 M | -393 M | -273 M | -160 M | -94.6 M | -33.8 M | -18.3 M | -9.63 M | - |
Interest Expense |
29 K | -383 K | 15 K | 134 K | 250 K | 82 K | 22 K | -64 K | -35 K | -23 K | -9 K | -3 K | -1 K | - |
EBITDA |
-431 M | -578 M | -546 M | -457 M | 599 M | -706 M | -392 M | -273 M | -160 M | -94.5 M | -33.8 M | -18.2 M | -9.59 M | - |
Operating Expenses |
474 M | 666 M | 555 M | 467 M | 518 M | 715 M | 484 M | 273 M | 160 M | 94.6 M | 33.8 M | - | - | - |
General and Administrative Expenses |
216 M | 275 M | 228 M | 183 M | 197 M | 346 M | 157 M | 51.7 M | 34.1 M | 22.2 M | 9.71 M | 3.38 M | 2.4 M | - |
All numbers in USD currency
Quarterly Income Statement Sage Therapeutics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
62.6 M | 61.9 M | 61.4 M | 61.1 M | 60.5 M | 60.1 M | 60 M | 59.9 M | 59.8 M | 59.7 M | 59.5 M | 59.4 M | 59.3 M | 59 M | 58.9 M | 58.8 M | 58.6 M | 58.4 M | 58.3 M | 52 M | 51.9 M | 51.9 M | 51.9 M | 51.7 M | 51.3 M | 48.5 M | 46.9 M | 46.7 M | 46.5 M | 44.3 M | 42 M | 37.5 M | 37.4 M | 37.3 M | 37.2 M | 33 M | 32.1 M | 31.6 M | 28.8 M | 28.7 M | 27.9 M | 25.7 M | 25.6 M | 19.6 M | 1.7 M | 1.65 M | 1.62 M | 1.51 M | 1.46 M | - | - | - | - | - | - | - | - | - |
Net Income |
-49.7 M | -62.2 M | - | -93.6 M | -103 M | -108 M | - | -202 M | -160 M | -147 M | - | -137 M | -126 M | -122 M | - | -130 M | -107 M | -95.8 M | 975 M | -106 M | -136 M | -127 M | -169 M | -180 M | -168 M | -163 M | -158 M | -123 M | -17 M | -74.6 M | -69.4 M | -73.7 M | -70.2 M | -56.8 M | -55.9 M | -37.8 M | -34.7 M | -30.5 M | -28.6 M | -24 M | -25 M | -16.9 M | -12.4 M | -9.47 M | -6.19 M | -5.79 M | - | -4.52 M | -4.66 M | - | - | - | - | - | - | - | - | - |
Revenue |
31.7 M | 14.1 M | - | 11.9 M | 8.65 M | 7.9 M | - | 2.72 M | 2.47 M | 3.29 M | - | 1.74 M | 1.5 M | 1.58 M | - | 1.44 M | 1.64 M | 1.58 M | 1.11 B | 1.64 M | 1.09 M | 2.29 M | 1.96 M | 3.57 M | 873 K | 465 K | 273 K | 90 M | 90 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 44 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-54 M | -67.5 M | - | -101 M | -111 M | -118 M | - | -212 M | -170 M | -155 M | - | -141 M | -128 M | -123 M | - | -131 M | -108 M | -96.5 M | 974 M | -107 M | -139 M | -132 M | -175 M | -187 M | -176 M | -170 M | -164 M | -129 M | -22.1 M | -78.1 M | -70.4 M | -74.4 M | -70.9 M | -57.5 M | -56.4 M | -38.1 M | -35 M | -30.7 M | -28.6 M | -24.1 M | -25.1 M | -16.9 M | -12.4 M | -9.47 M | -6.19 M | -5.79 M | - | -4.52 M | -4.66 M | - | - | - | - | - | - | - | - | - |
Interest Expense |
-6 K | 18 K | - | 9 K | 15 K | -12 K | - | -55 K | -41 K | -188 K | - | 30 K | 45 K | -24 K | - | 31 K | 44 K | 35 K | - | 76 K | -66 K | 155 K | - | -8 K | 16 K | 4 K | - | 10 K | 32 K | -8 K | - | -23 K | -20 K | -5 K | - | -7 K | -7 K | -4 K | - | -6 K | -9 K | 5 K | - | -1 K | -5 K | - | - | 1 K | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-53.8 M | -67.3 M | - | - | - | -117 M | - | - | - | -155 M | - | -141 M | -128 M | -123 M | - | -127 M | -107 M | -93.9 M | 974 M | -106 M | -138 M | -131 M | -175 M | -186 M | -176 M | -169 M | -164 M | -128 M | -21.9 M | -77.9 M | -70.4 M | -74.3 M | -70.8 M | -57.2 M | -56.4 M | -37.9 M | -34.9 M | -30.7 M | -28.6 M | -24 M | -25 M | -16.9 M | -12.4 M | -9.44 M | -6.17 M | -5.78 M | - | -4.48 M | -4.63 M | - | - | - | - | - | - | - | - | - |
Operating Expenses |
85.6 M | 81.5 M | - | 113 M | 120 M | 126 M | - | 215 M | 173 M | 159 M | - | 143 M | 130 M | 125 M | - | 132 M | 110 M | 98.1 M | 135 M | 109 M | 140 M | 134 M | 177 M | 191 M | 177 M | 170 M | 164 M | 129 M | 112 M | 78.1 M | 70.4 M | 74.4 M | 70.9 M | 57.5 M | 56.4 M | 38.1 M | 35 M | 30.7 M | 28.6 M | 24.1 M | 25.1 M | 16.9 M | 12.4 M | 9.47 M | 6.19 M | 5.79 M | - | 4.52 M | 4.66 M | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
62 M | 57.6 M | - | 53.2 M | 56 M | 52.6 M | - | 78.1 M | 75.6 M | 65.7 M | - | 61.5 M | 52.4 M | 46.5 M | - | 48.7 M | 43.3 M | 39.8 M | - | 35.1 M | 38.2 M | 70.1 M | - | 88.5 M | 88.2 M | 83.9 M | - | 53.7 M | 43.2 M | 28.8 M | - | 16.1 M | 15 M | 12.3 M | - | 8.99 M | 8.91 M | 7.13 M | - | 6.6 M | 6.46 M | 4 M | - | 2.87 M | 1.81 M | 1.62 M | - | 1.11 M | 801 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Sage Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
